Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study Evaluating the Safety and Pharmacokinetics of BMN 349 in Homozygous for the Z Mutation of Alpha 1 Antitrypsin Gene (PiZZ) and Heterozygous for the Z Mutation (PiMZ/MASH)
BioMarin Pharmaceutical
12 participants
Feb 21, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to assess the safety and tolerability of a single oral dose of BMN 349 in participants with PiZZ or PiMZ/MASH. Primary outcome measures include incidence of any adverse events (including serious adverse events, dose limit toxicities, and adverse events of special interest), incidence of any laboratory test abnormalities, incidence of lung function test abnormalities and 12-lead ECG parameters. Participants will receive a single dose of either BMN 349 or placebo and then monitored for safety and tolerability.
Eligibility
Inclusion Criteria3
- Participants must have confirmation of PiZZ or PiMZ genotype
- Females and males, of any race, 18 to 75 years of age
- Nonsmokers, defined as not using tobacco or nicotine-containing products for at least 6 months prior to Screening
Exclusion Criteria4
- International normalized ratio (INR) > 1.2
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels > 125 U/L
- Current or recent use of AAT augmentation therapy
- Participants with recent (last 3 months) diagnosis of pneumonia
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
250mg oral tablet
250mg oral tablet
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06738017